Monday, November 24, 2014 9:23:40 AM
Effective November 16, 2014, Amarantus BioScience Holdings, Inc. (the “Company”) entered into a Consulting Agreement (the “Consulting Agreement”) with NeuroAssets SARL (“NeuroAssets”), a company registered in Vevey, Switzerland, pursuant to which the Company has engaged NeuroAssets, on a non-exclusive basis, to provide the Company with certain consulting services, including services related to: gathering and processing of scientific literature and information, sourcing and due diligence regarding potential acquisitions and/or licensing, development of clinical and preclinical programs, performance of research, assistance with intellectual property and fundraising, and other strategic initiatives (the “Services”).
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM